Back to Search
Start Over
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)
- Source :
- Haematologica
- Publication Year :
- 2020
-
Abstract
- N/A
- Subjects :
- Oncology
medicine.medical_specialty
Cyclophosphamide
Chronic lymphocytic leukemia
Lymphoproliferative disorders
Ofatumumab
Antibodies, Monoclonal, Humanized
NO
chemistry.chemical_compound
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Chronic Lymphocytic Leukemia
Letters to the Editor
Minimal Residual Disease
Lymphoproliferative Disorders
business.industry
Front line
Hematology
medicine.disease
Settore MED/15
Minimal residual disease
Leukemia, Lymphocytic, Chronic, B-Cell
Fludarabine
Treatment Outcome
chemistry
N/A
Chronic Lymphocytic Leukemia, Lymphoproliferative Disorders
IGHV@
business
Rituximab
Vidarabine
medicine.drug
Subjects
Details
- ISSN :
- 15928721
- Volume :
- 105
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Haematologica
- Accession number :
- edsair.doi.dedup.....987461189c4c5399a54765f8d1e99f1d